Beat the Street: Investors eye US inflation; oil; BofA outlook; Eli Lilly
The state of the US economy, where interest rates and inflation are headed keeping investors wary of making big bets.
Significant tech outflows have been reported, shows Bank of America Global Research. Plus, Eli Lily’s diabetes drug gets the UK green light.
US inflation and tech industry concerns
Global investors' cautious approach due to awaiting US inflation data and its impact on interest rates. Concerns about the tech industry's recent decline. Positive news for the pharmaceutical industry with the approval of a diabetes drug from Eli Lilly in the United Kingdom.
Economic uncertainty and market hesitancy
Weak economic data from China contributing to global economic uncertainty. Concerns about prolonged high-interest rates and the challenges faced by the Federal Reserve. Worries about the Chinese economy and potential stimulus measures.
US dollar and Apple's stock
Price Senior market analyst Axel Rudolf discusses the strengthening US dollar, its impact on currencies, and China's restrictions on iPhones affecting Apple's stock price. Tension between China and the US, Apple's product unveiling timing, Bank of America's research on tech stocks, outlook for oil prices, the US dollar, yields, and tighter financial conditions.
Eli Lilly's
Details on outflows from equity funds, tech stocks, and Eli Lilly's diabetes drug approval. Mention of Kroger's earnings and opioid claims against the company. DocuSign's second-quarter results, GameStop's investigation by the US Securities and Exchange Commission, Chevron's liquefied natural gas projects strike in Australia, and potential impacts on gas prices. Updates on oil prices, the US dollar, and gold prices, along with a visual overview of the market before opening.
This information has been prepared by IG, a trading name of IG Markets Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients. See full non-independent research disclaimer and quarterly summary.
Start trading forex today
Find opportunity on the world’s most-traded – and most-volatile – financial market.
- Trade spreads from just 0.6 points on EUR/USD
- Analyse with clear, fast charts
- Speculate wherever you are with our intuitive mobile apps
See an FX opportunity?
Try a risk-free trade in your demo account, and see whether you’re onto something.
- Log in to your demo
- Take your position
- See whether your hunch pays off
See an FX opportunity?
Don’t miss your chance – upgrade to a live account to take advantage.
- Get spreads from just 0.6 points on popular pairs
- Analyse and deal seamlessly on fast, intuitive charts
- See and react to breaking news in-platform
See an FX opportunity?
Don’t miss your chance. Log in to take your position.
Live prices on most popular markets
- Equities
- Indices
- Forex
- Commodities
Prices above are subject to our website terms and agreements. Prices are indicative only. All share prices are delayed by at least 15 minutes.
Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 15 mins.
